This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Founded in 1997, 4SC currently has 83 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
4SC Discovery GmbH is a fully owned subsidiary of 4SC. It was incepted in December 2011 in order to provide fully integrated drug discovery services and innovative preclinical products from idea to IND.
They discovered the new principle of modulating antibodies, which act as partial inhibitors and thus balance the downstream response and controls bioactivity. This new antobody principle is representing a new class of drugs with an favourable safety profile and broad therapeutic window.
Their lead compound Adrecizumab is a first-in-class humanized monoclonal antibody against Adrenomedullin with excellent preclinical efficacy in acute kidney injury and sepsis and a good tolerability.
The company?s innovative approach of "personalized medicine" means tailoring treatments to a patient?s specific condition and to unmet medical needs. The company has submitted a NDA to the US FDA for its oral ghrelin agonist, macimorelin acetate (AEZS-130). The compound has the potential to become the first approved product that induces GH release to evaluate adult growth hormone deficiency (AGHD). Its product pipeline encompasses about half a dozen compounds in clinical trials and as many in preclinical development.